Collaboration With Cambridge Antibody Technology
In 1999, HGS signed a deal with the UK biopharmaceutical company Cambridge Antibody Technology to discover and develop antibody therapeutics. This deal generated belimumab, raxibacumab, mapatumumab and lexatumumab. In April 2012, the first three of these products form part of the six named by HGS in its public pipeline.
Read more about this topic: Human Genome Sciences
Famous quotes containing the words cambridge and/or technology:
“If we help an educated man’s daughter to go to Cambridge are we not forcing her to think not about education but about war?—not how she can learn, but how she can fight in order that she might win the same advantages as her brothers?”
—Virginia Woolf (1882–1941)
“Our technology forces us to live mythically, but we continue to think fragmentarily, and on single, separate planes.”
—Marshall McLuhan (1911–1980)